Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 2025-2032

  Kantharidis, Phillip ^a   El Osta, Assam ^a   DeSilva, Michelle ^a   Wall, Dominic M P ^b   Hu, Xiu F ^a   Slater, Alison ^a   Nadalin, Gabriella ^a   Parkin, John D ^b   Zalcberg, John R ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; EPIRUBICIN; GENE PRODUCT; GLYCOPROTEIN P; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS; METHYLATION; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOTTING, SOUTHERN; DAUNORUBICIN; DINUCLEOSIDE PHOSPHATES; DNA METHYLATION; DRUG RESISTANCE, MULTIPLE; EPIRUBICIN; EXONS; HUMANS; INTRONS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, T-CELL; P-GLYCOPROTEIN; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RESTRICTION MAPPING; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0030722392     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gottesmann, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
2. Licht, T., Pastan, I., Gottesmann, M. M., and Herrmann, F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann. Hematol., 69: 159-171, 1994.
3. Goldie, J. H., and Coldman, J. A. Genetic instability in the development of drug resistance. Semin. Oncol., 12: 222-230, 1985.
4. Galzer, R. I., and Rohlff, C. Transcriptional regulation of multidrug resistance in breast cancer. Breast Cancer Res. Treat., 31: 263-271, 1994.
5. Gottesmann, M. M., Hrycyna, C. A., Schoenlein, P. V., Germann, U. A., and Pastan, I. Genetic analysis of the multidrug transporter. Annual Rev. Genet., 29: 607-649, 1995.
6. Madden, M. J., Morrow, C. S., Nakagawa, M., Goldsmith, M. E., Fairchild, C. R., and Cowan, K. H. Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J. Biol. Chem., 268: 8290-8297, 1993.
7. Chin, K-V., Ueda, K., Pastan, I., and Gottesmann, M. M. Modulation of activity of the promoter of the human mdr1 gene by ras and p53. Science (Washington DC), 255: 459-462, 1992.
8. Rohlff, C., and Galzer, R. I. Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell. Signalling, 7: 431-443, 1995.
9. Stein, U., Walther, M., and Wunderlich, V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur. J. Cancer, 30: 1541-1545, 1994.
10. Borellini, F., Aquino, A., Josephs, S. F., and Glazer, R. J. Increased expression and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant HL-60 leukemia cells. Mol. Cell. Biol., 10: 5541-5547, 1990.
11. Ogura, M., Takatori, T., Sugimoto, Y., and Tsuruo, T. Identification and characterization of three DNA-binding proteins on the promoter of human MDR1 gene in drug-sensitive and resistant cells. Jpn. J. Cancer Res., 82: 1151-1159, 1991.
12. Ueda, K., Pastan, I., and Gottesmann, M. M. Isolation and sequence of the promoter region of the human multidrug resistance (P-glycoprotein) gene. J. Biol. Chem., 262: 17432-17436, 1987.
13. Laird, P. W., and Jaenisch, R. DNA methylation and cancer. Hum. Mol. Genet., 3: 1487-1495, 1994.
14. Yeivin, A., and Razin, A. Gene methylation patterns and expression. In: J. P. Jost and H. P. Saluz (eds.), DNA Methylation: Molecular Biology and Biological Significance, pp. 523-568. Basel: Berkhaeuser Verlag, 1993.
15. Wall, D. M. P., Sparrow, R., Hu, X. F., Nadalin, G., Zalcberg, J. R., Marschner, I. C., Van Der Weyden, M., and Parkin, J. D. Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, fluo-3. Eur. J. Cancer, 29: 1024-1027, 1993.
16. Beck, W. T., Mueller, T. J., and Tanzer, L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res., 39: 2070-2076, 1979.
17. Zalcberg, J. R., Hu, X. F., Wall, D. M., Mirski, S., Cole, S., Nadalin, G., De-Luise, M., Parkin, J. D., Vrazas, V., Campbell, L., and Kantharidis, P. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int. J. Cancer, 57: 522-528, 1994.
18. Hu, X. F., Slater, A., Wall, D. M., Kantharidis, P., Parkin, J. D., Cowman, A., and Zalcberg, J. R. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br. J. Cancer, 71: 931-936, 1995.
19. Hu, X. F., Slater, A., Wall, D. M., Parkin, J. D., Kantharidis, P., and Zalcberg, J. R. Cyclosporin A and PSC 833 prevent upregulation of mdr1 expression by anthracyclines in a human multidrug resistant cell line. Clin. Cancer Res., 2: 713-720, 1996.
20. DeSilva, M., Kantharidis, P., Wall, D. M., Campbell, L., Vrazas, V., Nadalin, G., Kaczmarczyk, S. J., Hu, X. F., Parkin, J. D., and Zalcberg, J. R. Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids. Br. J. Cancer, 73: 169-174, 1996.
21. Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., Von-Hoff, D. D., and Roninson, I. B. Quantitative analysis of the mdr1 (multidrug resistance) gene expression in human tumours by polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 87: 7160-7164, 1990.
22. Haaf, T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol. Ther., 65: 19-46, 1995.
23. Beck, W. T., Grogan, T. M., Willman, C. L., Cordon-Cardo, C., Parham, D. M., Kuttesch, J. F., Andreef, M., Bates, S. E., Berard, C. W., Boyett, J. M., Brophy, N. A., Head, D., Houghton, P. J., Srivastava, D. K., Lehnert, M., Leith, C. P., Paietta, E., Pavelic, Z. P., Rimsza, L., Roninson, I. B., Sikic, B. I., Twentyman, P. R., Warnke, R., and Weinstein, R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumours: consensus recommendations. Cancer Res., 56: 3010-3020, 1996.
24. Murphy, L. D., Herzog, C. E., Rudick, J. B., Fojo, A. T., and Bates, S. E. Use of the polymerase chain reaction in the quantitation of MDR-1 gene expression. Biochemistry, 29: 10351-10356, 1990.
25. Migeon, B. R. Insights into X chromosome inactivation from studies of species variation, DNA methylation and replication, and vice versa. Genet. Res., 56: 91-98, 1990.
26. Li, E., Beard, C., and Jaenisch, R. Role for DNA methylation in genomic imprinting. Nature (Lond.), 366: 362-365, 1993.
27. Sakai, T., Toguchida, J., Ohtani, N., Yandell, D. W., Rapaport, J. M., and Dryja, T. P., Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet., 48: 880-888, 1991.
28. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
29. Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., Linehan, W. M., and Baylin, S. B. Silencing of the VHL tumour suppressor gene by DNA methylation in renal cell carcinoma. Proc. Natl. Acad. Sci. USA, 91: 9700-9704, 1994.
30. Ferguson, A. T., Lapidus, R. G., Baylin, S. B., and Davidson, N. E. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate the estrogen receptor gene expression. Cancer Res., 55: 2279-2283, 1995.
31. Lincke, C. R., Smit, J. J. M., van der Velde-Koerts, T., and Borst, P. Structure of the human MDR3 gene and physical mapping of the human MDR locus. J. Biol. Chem. 266: 5303-5310, 1991.
32. -. Cancer Res., 47: 3672-3678, 1987.
33. Comb, M., and Goodman, H. M. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res., 18: 3975-3982, 1990.
34. Klempnauer, K-H. Methylation-sensitive DNA binding by v-myb and c-myb proteins. Oncogene, 8: 111-115, 1993.
35. Prendergast, G. C., and Ziff, E. B. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science (Washington DC), 251: 186-189, 1991.
36. Bednarik, D. P., Ducket, C., Kim, S. U., Perez, V. L., Griffis, K., Guenther, P. C., and Folks, T. M. DNA CpG methylation inhibits binding of NF-κ B proteins to the HIV-1 long terminal repeat cognate DNA motifs. New Biol., 3: 969-976, 1991.
37. Holler, M., Westin, G., Jiricny, J., and Schaffner, W. Sp1 transcription factor binds DNA and activates transcription even when the binding site is CpG methylated. Genes Dev., 2: 1127-1135, 1988.
38. Harrington, M. A., Jones, P. A., Imagawa, M., and Karin, M. Cytosine methylation does not affect binding of transcription factor Sp1. Proc. Natl. Acad. Sci. USA, 85: 2066-2070, 1988.
39. Brandeis, M., Frank, D., Keshet, I., Siegfried, Z., Mendelsohn, M., Nemes, A., Temper, V., Razin, A., and Cedar, H. Sp1 elements protect a CpG island from de novo methylation. Nature (Lond.), 377: 435-438, 1994.
40. Radtke, F., Hug, M., Georgiev, O., Matsuo, K., and Schaffner, W. Differential sensitivity of zinc finger transcription factors MTF-1, Sp1 and Krox-20 to CpG methylation of their binding sites. Biol. Chem., 377: 47-56, 1996.
41. Antequera, F., Boyes, J., and Bird, A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell, 62: 503-514, 1990.
42. Meehan, R. R., Lewis, J. D., McKay, S., Kleiner, E. L., and Bird, A. P. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell, 58: 499-507, 1989.
43. Meehan, R. R., Lewis, J. D., and Bird, A. P. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res., 20: 5085-5092, 1992.